Armata Pharmaceuticals, Inc.
ARMPAMEXHealthcareBiotechnology
Latest quote
$5.05
+$0.68 · +15.38%
ARMP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
17
Overpriced
Momentum
33
Weakening
Sentiment
42
Mixed
Risk resilience
26
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteArmata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Deborah L. Birx
- Listed since
- May 20, 1994
- Employees
- 61
Market position
- Volume
- 105.5K
- 0.82× average
- Average volume
- 128.55K
- Average daily volume
- Market cap
- 187.23M USD
- Beta
- 1.33
- Market reference 1
Continue in GoAI
Research ARMPresearch.disclaimer